May 20, 2025
New Analysis Describes Flexibility Associated with Companion Diagnostic Development for Rare Cancer Biomarkers
A new analysis from Friends of Cancer Research (Friends) characterizes flexibilities utilized in the development of companion diagnostics (CDx). Reviewing Summary of Safety and Effectiveness Data (SSED) documents from FDA Premarket Approval applications (PMA) for non-small cell lung cancer (NSCLC), the analysis describes how alternative sample sources can be leveraged for CDx validation, particularly when sample…
Read More